REFERENCES
- Bushinsky DA, Riera GS, Favus MJ, Coe FL. Evidence that blood ionized calcium can regulate serum 1.25 (OH)2D3 independently of parathyroid hormone and phosphorous in the rat. J Clin Invest 1985; 76: 1599–1604.
- Falsenfeld AJ, Gutman RA, Llach F, Harrelson JM. Osteomalacia in chronic renal failure: A syndrome previously reported only with maintenance dialysis. Am J Nephrol 1982; 2: 147–154.
- Freeman S, Freeman WMC. Phosphorus retention in children with chronic renal insufficiency. Am J Dis Child 1941; 61: 981–1002.
- Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregorie I, Idrissi A, Garabedian M. Calcium carbonate, an aluminium-free agent for the control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 1986; 29 (Suppl 18): 114–119.
- Gonella M, Calabrese G, Vagelli G, Pratesi G, Lamon S, Talarica S. Effects of high CaCO3 supplements on serum calcium and phosphorous in patients on regular hemodialysis. Clin Nephrol 1985; 24: 147–150.
- Goodman WG, Henry DA, Horst R, Nudelman RK, Alfrey AC, Coburn JW. Parenteral aluminium administration in the dog. II. Induction of osteomalacia and effect vitamin D metabolism. Kidney Int 1984; 25: 370–375.
- Gray RW, Napoli JL. Dietary phosphate deprivation increases 1,25-Dihydroxyvitamin D3 synthesis in vitro. J Biol Chem 1983; 258: 1152–1154.
- Hackeng WHL, Lips P, Netelenbos JC, Lips CJM. Clinical implications of intact parathyroid hormone (PTH) versus total immunoreactive PTH in normal subjects and hyperparathyroid patients. J Clin Endocrinol Metab 1986; 63: 447–453.
- Krueger GL, Morris TK, Suskind RR, Widner EM. The health effects of aluminium compounds in mammals. CRC Crit Rev Toxicol 1984; 13: 1–24.
- Klein GL, Lee TC, Bishop JE, Vaccaro ML, Jongen M, Kurokawa K, Coburn JW, Norman AW. The effects of aluminium loading on the renal response to parathyroid hormone in the vitamin D-replete rat. Biochem Med Metab Biol 1986; 36: 363–368.
- Lindall AW, Elting J, Ells J, Roos BA. Estimation of biologically active intact parathyroid hormone in normal and hyperparathyroid sera by sequential N-terminal immunoextraction and midregion radioimmunoassay. J Clin Endocrinol Metab 1983; 57: 1007–1013.
- Makoff DL, Gordon A, Franklin SS, Gerstein AR, Maxwell MH. Chronic calcium carbonate therapy in uremia. Arch Intern Med 1969; 123: 15–21.
- Masselot JP, Adhemar JP, Jaudon MC, Kleinknect D, Galli A. Reversible dialysis encephalopathy: role for aluminium containing gels. Lancet 1978; 2: 1386–1387.
- Meyrier A, Marsac J, Richet G. The influence of high calcium carbonate intake in bone disease in patients undergoing hemodialysis. Kidney Int 1973; 4: 146–153.
- Moriniere P, Roussel A, Tahiri Y, De Fremont JF, Maurel G, Jaudon MC, Gueris J, Fourinier A. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: Disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc EDTA 1982; 19: 784–785.
- Poisson M, Mashaly R, Lebkin B. Dialysis encephalopathy: recovery after interruption of aluminium intake. Br Med J 1978; 2: 1610–1611.
- Reinhardt TA; Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies. J Clin Endocrinol Metab 1984; 58: 91–98.
- Slatopolsky E, Weerts C, Lopes-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157–161.